Romiplostim

Introduction Overview

Generic Name

romiplostim

Brand Name

Nplate

Dosage Form

injection (125 mcg, 250 mcg, 500 mcg)

Drug Class

Platelet-stimulating agents, Thrombopoietin receptor agonists

Pharmacokinetics

Absorption: Romiplostim, administered subcutaneously, exhibits absorption with a median time to peak serum concentration ranging approximately between 7 to 50 hours post-dose, depending on the administered dose and patient factors. The bioavailability of romiplostim after subcutaneous injection is not explicitly characterized in absolute terms, but it demonstrates sufficient systemic exposure to effectively stimulate platelet production. Factors such as injection site and patient immune status may influence absorption kinetics.

Distribution: After absorption, romiplostim distributes primarily within the vascular compartment and extracellular fluid. Due to its protein nature, it has a limited volume of distribution. Being a large molecular weight thrombopoietin mimetic peptide, it does not cross cellular membranes readily nor the blood-brain barrier. Binding affinity to thrombopoietin receptors on megakaryocytes localizes activity within the bone marrow environment.

Metabolism: Romiplostim is a peptibody, metabolized primarily through proteolytic degradation pathways typical of protein therapeutics. It undergoes catabolism into small peptides and amino acids by reticuloendothelial and cellular proteases without involvement of classical hepatic cytochrome P450 enzymatic systems. Its degradation products are biologically inactive.

Elimination: Clearance of romiplostim from the circulation is primarily via binding to thrombopoietin receptors with ensuing internalization and lysosomal degradation, in addition to proteolytic catabolism. The elimination half-life exhibits considerable interpatient variability, generally ranging from 1 to 34 days, related to receptor-mediated clearance mechanisms and disease states influencing receptor density and binding affinity. No significant renal or hepatic elimination pathways have been observed, consistent with its protein structure and metabolism.

Dosage Forms

Available Dosage Forms:
Nplate is provided as single-dose lyophilized powder vials for reconstitution and subcutaneous injection, available in strengths of 125 mcg, 250 mcg, and 500 mcg of romiplostim per vial.

Dosages for Adults and Adolescents:
For chronic immune thrombocytopenia (ITP) in adults and pediatric patients aged 1 year and older, the initial dose is 1 mcg/kg body weight, administered once weekly via subcutaneous injection. Dosage adjustments are made in increments of 1 mcg/kg weekly until a safe platelet count (≥ 50 x 10^9/L) is achieved. The maintenance dose is individualized and aimed to sustain platelet counts sufficient to reduce bleeding risk, not to normalize platelet counts.

Maximum dosing limits are set at 10 mcg/kg per week, with treatment to be discontinued if no clinically important platelet response is observed after 4 weeks at the maximum dose.

For hematopoietic syndrome of acute radiation syndrome (HS-ARS), a single subcutaneous dose of 10 mcg/kg is administered as soon as possible after radiation exposure.

Specific Patient Populations:
Dosing modifications are advised based on platelet count responses and changes in body weight, with pediatric dosing requiring reassessment every 12 weeks. Safety monitoring is critical in special populations such as patients with hepatic or renal impairments; however, no formal dose adjustments have been clearly defined due to limited pharmacokinetic alterations in these groups. Clinical caution is recommended in patients with a history of blood or bone marrow cancers, bleeding disorders, or splenectomy. Pregnant and breastfeeding patients should avoid Nplate due to insufficient safety data.

Mechanism Of Action

Romiplostim is a thrombopoietin receptor agonist that functions by mimicking the biological effects of endogenous thrombopoietin (TPO), the primary physiological regulator of platelet production. Structurally, it is a peptibody that binds specifically to and activates the TPO receptor (c-Mpl) on megakaryocyte progenitor cells in the bone marrow.

Upon binding to the extracellular domain of the TPO receptor, romiplostim triggers receptor dimerization, initiating intracellular signaling cascades predominantly via the JAK-STAT (Janus kinase-signal transducer and activator of transcription), MAPK (mitogen-activated protein kinase), and PI3K/AKT pathways. These signaling pathways promote proliferation and differentiation of megakaryocytes, the bone marrow cells responsible for platelet production.

Through this receptor activation, romiplostim effectively increases the number and maturation of megakaryocytes, leading to elevated platelet production and a corresponding rise in circulating platelet counts. This mechanism counteracts the thrombocytopenia observed in immune thrombocytopenic purpura (ITP), where platelet destruction is accelerated by autoimmune processes.

Clinically, romiplostim differs from other thrombopoietin receptor agonists, such as eltrombopag, in its molecular structure and receptor binding site, offering an alternative treatment approach for patients resistant to other therapies. The robust receptor activation and sustained platelet response have been demonstrated in multiple clinical trials, underpinning its use in reducing bleeding risk in chronic ITP and improving survival in patients exposed to high-dose radiation leading to hematopoietic syndrome.

Pharmacological Actions

Stimulates platelet production by acting as a thrombopoietin receptor agonist.
Promotes proliferation and differentiation of megakaryocyte progenitor cells in the bone marrow.
Mimics endogenous thrombopoietin activity, enhancing thrombopoiesis.
Modulates JAK-STAT, MAPK, and PI3K/AKT intracellular signaling pathways upon receptor binding.
Increases circulating platelet counts to reduce bleeding risk in thrombocytopenic patients.
Exhibits targeted receptor-mediated action without broad immunosuppressive effects.
Demonstrates prolonged half-life enabling once-weekly subcutaneous dosing.
Does not induce platelet normalization but maintains counts above bleeding risk thresholds.
Shows efficacy in autoimmune-mediated platelet destruction settings, including chronic ITP.
Supports hematopoietic recovery post-radiation exposure in acute radiation syndrome.
Displays minimal interaction with cytochrome P450 enzymes due to peptide structure.
Induces transient bone marrow reticulin fiber increases that may be reversible.
Has no direct chemotherapeutic or cytotoxic activity.
Mediates effects independent of thrombopoietin endogenous hormone levels.
Enables individualized dosing based on patient platelet responses and weight.

Therapeutic Or Clinical Uses

Treatment of chronic immune thrombocytopenic purpura (ITP) in adults with insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Management of ITP in pediatric patients aged 1 year and older with persistent low platelet counts unresponsive to conventional therapy.
Increases platelet counts in patients at risk of serious bleeding caused by thrombocytopenia.
Treatment of hematopoietic syndrome of acute radiation syndrome (HS-ARS) to improve survival following myelosuppressive radiation exposure.
Alternative therapy for patients intolerant or refractory to standard ITP treatments.
Reduction of bleeding episodes in chronic ITP through sustained platelet production.
Supportive care in radiation emergencies involving bone marrow suppression.
Used in clinical settings as a thrombopoietin receptor agonist to stimulate platelet recovery.
Adjunct therapy to reduce need for platelet transfusions in thrombocytopenic patients.
FDA-approved for subcutaneous weekly administration in ITP and single dose in HS-ARS.
Applicable in patients with prior splenectomy and chronic refractory thrombocytopenia.
Utilized as part of therapeutic regimens that require platelet count elevation to improve hemostasis.
May be employed under clinical guidance when other immune-modulating treatments fail.
Supports platelet homeostasis in immune-mediated destruction contexts.
Applied in situations requiring rapid platelet count recovery to prevent hemorrhagic complications.

Side Or Adverse Effects

Headache occurring in approximately 35% of patients, ranging from mild to severe.
Joint pain reported in about 26% of patients undergoing therapy.
Dizziness reported in 17% of patients; informational monitoring advised.
Muscle pain affecting approximately 14% of those treated.
Pain localized to arms, legs, or shoulders in 13% of cases.
Abdominal pain reported by roughly 11% of patients.
Shoulder pain occurring in about 8% of treated individuals.
Trouble sleeping or insomnia reported in 16% of patients.
Indigestion and gastrointestinal discomfort found in 7% of patients.
Numbness or tingling sensations in hands or feet reported in 6% of cases.
Serious allergic reactions including hives, swelling, and breathing difficulty.
Potential for increased risk of thromboembolic events such as stroke or blood clots in lungs or legs.
Signs of bone marrow fibrosis, including increased reticulin, necessitating periodic monitoring.
Possible otitis media manifestations, especially in pediatric patients.
Increased risk of bleeding rebound upon treatment discontinuation requiring careful tapering.

Precautions

Use with caution in patients with history of blood or bone marrow cancers, including leukemia or myelodysplastic syndromes.
Careful monitoring recommended for patients with pre-existing liver or kidney disease.
Regular blood counts required to detect bone marrow fibrosis or other hematologic abnormalities.
Avoid attempts to normalize platelet counts; treatment aims to reduce bleeding risk without overcorrection.
Increased risk of thromboembolic complications; monitor for signs of blood clots.
Pregnancy should be avoided due to unknown fetal risk; participation in pregnancy registries advised if used.
Breastfeeding is contraindicated during Nplate therapy.
Not indicated for thrombocytopenia from causes other than ITP or radiation-induced hematopoietic syndrome.
Patients should be educated on signs of allergic reactions and advised to seek immediate care if they occur.
Dose adjustments should be based on platelet monitoring and clinical response.
Avoid activities with high bleeding risk during therapy and especially in the weeks following discontinuation.
Inform healthcare providers of all concomitant medications, supplements, or herbal products.
Ensure adherence to dosing schedule to maintain therapeutic platelet levels.
Use cautiously in patients who have undergone splenectomy due to altered platelet dynamics.
Frequent clinical and laboratory assessments necessary to balance efficacy and safety.

Warnings

Nplate is not curative and does not normalize platelet counts in immune thrombocytopenia (ITP).
Serious risk of thromboembolism including stroke, pulmonary embolism, and deep vein thrombosis.
Discontinue or adjust therapy if platelet response is insufficient after 4 weeks at maximum dose.
Monitoring of bone marrow changes required due to possible development of marrow fibrosis or reticulin deposition.
Risk of bleeding may increase transiently after stopping treatment; patients should take precautions.
Avoid use in patients allergic to romiplostim or its components.
Potential increased risk of blood cancers with long-term use, especially in patients with myelodysplastic syndromes.
Not recommended for thrombocytopenia related to myelodysplastic syndrome or other causes beyond ITP and radiation.
Patients should be informed about the delay of up to 4 weeks before therapeutic effects are realized.
Risk of serious allergic reactions including anaphylaxis; immediate medical attention required if symptoms present.
Use caution in patients with history of clotting disorders or bleeding risk.
Renal and hepatic impairments may necessitate closer monitoring but formal dose adjustments are not specific.
Risk of otitis media and infections particularly in pediatric patients; vigilance required.
Ensure patients understand that dose individualization is essential for safe and effective use.
Discontinuation requires close follow-up due to possible rebound thrombocytopenia and bleeding.

Contraindication

Known hypersensitivity or allergy to romiplostim or any component of the formulation.
Not indicated for treatment of thrombocytopenia caused by myelodysplastic syndrome or other non-ITP causes.
Contraindicated in patients with history of trombopoietin receptor agonist hypersensitivity.
Avoid use in breastfeeding mothers due to unknown safety.
Should not be used to normalize platelet counts beyond target hemostatic thresholds.
Contraindicated in patients with active significant thrombotic or thromboembolic events.
Not recommended for patients with uncontrolled bleeding not related to thrombocytopenia.
Avoid in patients with hypersensitivity to inactive ingredients such as polysorbate 20.
Contraindicated if patient has history of severe allergic reactions to biologic protein therapeutics.
Not approved for use in pregnancy; avoid unless potential benefits outweigh risks.
Use is contraindicated if risk of exacerbating bone marrow fibrosis outweighs benefits.

Drug Interactions

No direct cytochrome P450 enzyme mediated interactions due to peptide nature of romiplostim.
Potential additive risk of thrombosis when combined with other pro-thrombotic agents.
Concomitant use with immunosuppressants or corticosteroids may alter immune-mediated thrombocytopenia dynamics.
Caution when administered with anticoagulants or antiplatelet drugs due to bleeding and clotting risk modification.
No known significant interactions with herbal supplements but clinical caution advised.
Continuous monitoring advised when combined with other hematopoietic growth factors or agents affecting platelet counts.
Possible altered pharmacodynamic response with drugs affecting bone marrow function.
No significant impact on absorption or metabolism of oral medications due to injection route and protein structure.
Interactions with blood products, such as platelet transfusions, should be managed clinically.
Monitor platelet counts closely when starting or stopping drugs that affect platelet function or coagulation.
Regular laboratory evaluation necessary to detect any unexpected interactions during therapy.
No documented interactions with vitamins but comprehensive medication review recommended.
Potential competition at thrombopoietin receptor sites with experimental or investigational agents.
Limited data on interactions with live vaccines; clinical discretion advised.
Patients should inform healthcare providers of all concurrent medications to evaluate potential effects.

Preparations Of The Drug

Nplate supplied as lyophilized powder in single-dose vials containing 125 mcg, 250 mcg, or 500 mcg of romiplostim.
Inactive ingredients include L-histidine, mannitol, polysorbate 20, sucrose, and hydrochloric acid for pH adjustment.
Vials require reconstitution with sterile water before subcutaneous injection.
Storage prior to use at 2°C to 8°C (36°F to 46°F) in original carton protected from light.
Unopened vials may be kept at room temperature up to 25°C (77°F) for a single period of up to 30 days; do not refrigerate again after warming.
Do not freeze vials to maintain protein stability and efficacy.
Administered exclusively via subcutaneous injection once weekly for ITP indications.
Single dose injection for HS-ARS patients requiring urgent treatment post-radiation exposure.
Packaging includes detailed prescribing information and dosing guides for healthcare professionals.
Manufactured by Amgen Inc., distributed with FDA-approved J code J2802 for billing and reimbursement.
Strict aseptic technique required during reconstitution and administration.
Patients require education on injection technique and injection site rotation to minimize local reactions.
Preparation protocols address avoidance of protein aggregation and maintain sterility.
Disposal instructions in compliance with biohazard and pharmaceutical waste regulations.
Pharmaceutical grade excipients optimized for peptide stability and patient safety.